A Smarter Path to Hormonal Health and Vitality

Abstract

Welcome. As a clinician with a diverse background in chiropractic, advanced practice nursing, and functional medicine, I am deeply committed to an integrative, evidence-based approach to health. This educational post will guide you through the intricate and often misunderstood world of hormones, debunking long-held myths and presenting a modern, holistic paradigm for wellness. We will critically re-examine the flawed Women’s Health Initiative (WHI) study, exposing how the use of synthetic hormones and improper delivery systems created a legacy of fear. We will explore the profound differences between bioidentical progesterone and synthetic progestins and present compelling data that vindicates estrogen, revealing its protective role against breast cancer. This journey will also dismantle myths surrounding testosterone, clarifying its crucial role in both men and women for cognitive function, mental health, cardiovascular wellness, and pain management. We will explore the physiological underpinnings of bone health, contrasting outdated bisphosphonate therapies with a superior, hormone-centric approach. Throughout this discussion, I will integrate the principles of integrative chiropractic care, demonstrating how restoring structural and neurological integrity is foundational to achieving optimal hormonal balance and preventing the chronic diseases of aging. My goal is to empower you with knowledge, moving from fear and misinformation to clarity and confidence in your health decisions.

---

Unraveling the Women’s Health Initiative: A Critical Re-Examination

Let’s begin by asking a fundamental question: Why are you here, reading this today? Perhaps it’s because the conventional health approaches you’ve encountered haven’t provided the answers or the well-being you’re seeking. This is a common story in my practice. People feel unwell, unheard, and confused by conflicting information, especially when it comes to hormones.

My journey and yours often start with a desire to understand the “why.” This is particularly true when we look at the history of hormone replacement therapy (HRT). Let’s travel back to the pivotal Women’s Health Initiative (WHI) study, a trial whose initial results, reported in 2002, radically altered our perception of hormones and left a legacy of fear that persists to this day.

But what if the study’s foundation was flawed from the start? Let’s consider a hypothetical. What if the WHI had used 17-beta estradiol delivered via a non-oral route, like a patch, instead of oral conjugated equine estrogens (Premarin)? And what if they had used bioidentical progesterone instead of a synthetic progestin like medroxyprogesterone acetate (Provera)?

The Critical Importance of Delivery Systems and Molecular Structure

To understand why this distinction is so crucial, we must look at our physiology. When you take a hormone in an oral pill form, it undergoes first-pass metabolism in the liver.

• Portal Circulation: Blood from your intestines goes directly to the liver through the portal vein.
• Liver Metabolism: The liver works hard to process this concentrated dose of the oral hormone. In response, it produces other substances, including an increased amount of clotting factors.
• Increased Clotting Risk: This is precisely why oral estrogen, found in medications like birth control pills and Premarin, is associated with an elevated risk of blood clots.

One of the most important benefits of estrogen is its cardioprotective effect. However, administering it orally simultaneously increases clotting factors, effectively canceling that benefit, since most heart attacks and strokes involve clot formation. The WHI concluded that estrogen didn’t help, but the reality is that they were using the wrong molecule (conjugated equine estrogens) and the wrong delivery system (oral). Had the study used 17-beta estradiol—the exact molecule our bodies are designed to use—and administered it transdermally, bypassing intensive liver metabolism, the outcomes would have been dramatically different.

Now, let’s look at progesterone. Has natural, bioidentical progesterone ever been shown to increase the risk of breast cancer in any credible study? The answer is a resounding no. The WHI used a synthetic progestin, Provera. We wouldn’t be having this conversation today if we had used the correct hormone molecules and delivery systems. The standard of care would be clear: as soon as a woman enters menopause, she should begin estrogen and progesterone therapy for the long-term health of her heart, bones, and brain.

The Lasting Impact and Ultimate Vindication of Estrogen

I was in private practice when the 2002 WHI results were published in the Journal of the American Medical Association (JAMA) and splashed across the cover of TIME magazine. Fear sells. The report, titled “The Truth About Hormones,” scared millions of women. I had to hire an additional staff member just to field panicked calls from patients wanting to stop their hormones.

In my clinical practice at our Chiropractic & Functional Medicine Clinic, I see the downstream effects every day. How many women today are suffering from cognitive decline, osteoporosis, and heart disease that could have been mitigated? Depriving an entire generation of women of protective estrogen has had devastating consequences.

The story gets even more compelling over time. Follow-up reports on the same WHI cohort have been nothing short of vindicating for estrogen.

• An 18-year follow-up published in JAMA stated, “Estrogen plus progestin was not associated with increased all-cause, cardiovascular, or cancer mortality…” (Manson et al., 2017). Essentially, the researchers were saying, “Never mind.”
• A 2020 study, also in JAMA, delivered a bombshell. Women in the estrogen-only arm for about seven years had a lower incidence of breast cancer and were less likely to die from breast cancer over their lifetimes (Chlebowski et al., 2020).

Let that sink in. Estrogen is the only medicine in history shown in a prospective, randomized, placebo-controlled, long-term trial to reduce the chance of both getting breast cancer and dying from it. And this result was with Premarin, a “dirty” estrogen. Imagine the protective power of bioidentical 17-beta estradiol.

Understanding Progesterone vs. Progestins: A Critical Distinction

It is critically important to distinguish between progesterone and progestins. They are not the same, and this confusion is at the heart of much of the misinformation surrounding HRT.

• Progesterone (P4): This is the natural, bioidentical hormone our bodies produce. It has a specific, beneficial molecular structure.
• Progestins: These are synthetic compounds designed to mimic some of the effects of progesterone. Examples include medroxyprogesterone acetate and norethindrone acetate. They have different molecular structures and vastly different metabolic effects.

When I see a new study claiming “hormone replacement therapy” causes a health issue, the first thing I do is look at the abstract to identify the molecules used. Invariably, the culprit is a synthetic progestin.

Progesterone’s role is often tragically minimized, especially in women who have had a hysterectomy. The conventional thinking, “No uterus, no need for progesterone,” is a fundamentally flawed and harmful perspective. It ignores the progesterone receptors in the brain, bones, and cardiovascular system. In my clinical practice, every menopausal patient is on progesterone at some point. If a woman presents with insomnia, I frequently initiate treatment with progesterone, as it is unequivocally the most effective remedy for insomnia in menopausal women.

A crucial point of caution: progesterone cream is not sufficient for uterine protection. Progesterone is a large molecule that does not absorb well through the skin to achieve adequate systemic blood levels. If a uterus is present, progesterone must be delivered systemically—orally, sublingually, or as a vaginal suppository—to ensure the uterine lining is protected from the proliferative effects of unopposed estrogen (Hargrove et al., 1989).

The Menstrual Cycle: A Symphony of Hormones

To appreciate the role of hormones, we must understand their natural rhythm. The menstrual cycle is a beautiful, synergistic dance, not a battle for dominance.

1. Follicular Phase (First Half): As a dominant follicle grows, it produces estrogen, which causes the uterine lining (endometrium) to thicken.
2. Luteal Phase (Second Half): After ovulation, the corpus luteum produces progesterone. Progesterone’s role is to stabilize the endometrium, halting estrogen-driven proliferation and preparing the tissue for implantation.
3. Menstruation: If implantation does not occur, the drop in progesterone triggers the shedding of the uterine lining.

It’s a mistake to say that progesterone “opposes” estrogen. They work synergistically as a team. Studying a hormone in isolation will never provide a complete understanding of its effects.

Testosterone: A Human Hormone Essential for All

One of the most persistent myths is that testosterone is exclusively a male hormone. Let’s set the record straight: testosterone is a human hormone.

• A woman produces more testosterone over her lifetime than she does estrogen.
• The androgen receptor is located on the X chromosome, which every individual possesses.
• Ignoring testosterone deficiency in women, especially after a hysterectomy with ovary removal, is a grave oversight. We are taking out three essential hormones (estrogen, progesterone, and testosterone) and often replacing only one poorly.

In my practice, optimizing testosterone is crucial. It’s a key factor in managing the number one symptom of menopause: pain. Joint, bone, and muscle pain are the body’s first signals of a critical hormonal deficit.

Debunking the Myth: Testosterone and Prostate Cancer

For decades, physicians have feared that testosterone therapy is like “adding fuel to the fire” of prostate cancer. Dr. Abraham Morgentaler of Harvard traced this myth to a single, 100-year-old study of only two men. His career has been dedicated to dismantling this myth with rigorous science.

His research showed that low testosterone, not replacement therapy, is an independent risk factor for developing prostate cancer. This led to the Prostate Saturation Model. Dr. Morgentaler found that prostate androgen receptors become fully saturated at a testosterone level of around 200 ng/dL. This means that for a man with a baseline level of 350 ng/dL, optimizing his level to 950 ng/dL adds zero additional testosterone to his prostate. The receptors are already full.

The current consensus is that if a man has been successfully treated for prostate cancer and shows no evidence of recurrence, testosterone therapy can and should be initiated immediately to restore his quality of life.

Beyond “Normal”: The Power of Hormone Optimization

One of the most profound shifts in modern functional medicine is the move from the “normal range” to the “optimal range.” A lab’s reference range is just a statistical average; it says nothing about what is healthy.

A study on dementia found that men with testosterone levels in the lowest quintile had an 80% higher risk of developing dementia than men in the highest quintile (Yeap et al., 2021). A man with a “low normal” level of 325 ng/dL has a significantly higher risk than a man at an optimal 850 ng/dL. There is only suboptimal and optimal.

My goal is to restore a patient’s hormone levels to the upper quartile of the range for a young, healthy adult—a level that is protective against disease and promotes vitality.

The Receptor Model of Cancer and the Protective Role of Hormones

To understand why old fears were misplaced, we must look at the cellular level. The Receptor Model for Cancer explains that hormones exert their effects by binding to specific receptors. The problem arises with synthetic molecules like progestins, which can block protective receptor pathways, effectively removing the brakes on cell growth.

This is what happened in the WHI. The synthetic progestin blocked protective pathways, leading to an observed increase in breast cancer. It wasn’t the estrogen; it was the progestin.

In stark contrast, compelling evidence shows that testosterone has anti-inflammatory and anti-proliferative (anti-cancer) effects in breast tissue. Dr. Rebecca Glaser, a breast cancer surgeon, has published extensively on this.

• A massive Nurses’ Health Study followed nearly 30,000 nurses for 24 years. It found that women who had their ovaries removed (inducing surgical menopause) had a significantly higher risk of all-cause mortality, heart disease, and lung cancer compared to those who conserved their ovaries (Parker et al., 2013). Our natural hormones provide powerful, lifelong protection.

Rethinking Osteoporosis: Hormones for Bone Health

The conventional approach to osteoporosis, using drugs like bisphosphonates, is deeply flawed. These drugs work by blocking osteoclasts, the cells that break down old bone. This is like paving over a road full of potholes without clearing out the crumbling asphalt. You accumulate old, weak, brittle bone that may look denser on a scan but is not structurally sound.

The true key is promoting healthy bone remodeling, and hormones are the master regulators. A landmark study showed that patients on hormone pellet therapy experienced an average 8.3% increase in bone density per year. This vastly outperforms bisphosphonates (1-2% annual increase). By restoring hormonal levels of estrogen and testosterone, we effectively turn back the clock on skeletal health.

Testosterone and the Heart: A Cardiologist’s Best Friend

One of the most dangerous myths is that testosterone is bad for the heart. This scare originated from a thoroughly debunked 2016 VA study that used a flawed high-risk population and manipulated data to reverse its own raw findings.

The scientific reality is that low testosterone is an independent risk factor for cardiovascular disease. Optimal testosterone is a cardiologist’s best friend because it:

• Improves endothelial function, keeping arteries smooth.
• Increases arterial elasticity, helping regulate blood pressure.
• Enhances insulin sensitivity, a primary driver of heart disease.
• Exerts anti-inflammatory effects, quelling the inflammation that underlies heart attacks.

Integrative Chiropractic Care: Restoring Foundational Health

This is where the principles of integrative chiropractic care and functional medicine become so vital. The body is an interconnected system where structure governs function. Hormonal balance cannot be fully achieved if the underlying neurological and structural systems are compromised.

• Nervous System Regulation: The endocrine system is under the direct control of the nervous system. Chiropractic adjustments correct spinal misalignments (subluxations), restoring proper nerve flow between the brain and the endocrine glands. This optimizes the function of the hypothalamic-pituitary-adrenal-ovarian (HPAO) axis, the master communication network governing hormone production.
• Stress Reduction: Adjustments can shift the autonomic nervous system from a dominant “fight-or-flight” (sympathetic) state to a more relaxed “rest-and-digest” (parasympathetic) state. This is crucial because chronic stress elevates cortisol, which can disrupt the entire endocrine system and steal the building blocks for sex hormone production.
• Holistic Assessment: As a Doctor of Chiropractic, I have a comprehensive understanding of the situation. Low back pain may be connected to fatigue, low mood, systemic inflammation, and hormonal imbalance. This integrative perspective allows me to educate patients on the connections between their spine, nervous system, and hormonal health.

By combining evidence-based hormone optimization with the foundational principles of chiropractic care, we address the root cause of dysfunction. We don’t just replace a missing hormone; we restore the body’s innate intelligence and create a synergistic effect for true, resilient health. This is the future of healthcare—a proactive, personalized, and integrative approach that empowers you to live a longer, healthier, and more vibrant life.

---

References

Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA, 324(4), 369–380.

Hargrove, J. T., Maxson, W. S., Wentz, A. C., & Burnett, L. S. (1989). Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstetrics and Gynecology, 73(4), 606–612.

Manson, J. E., Aragaki, A. K., Rossouw, J. E., et al. (2017). Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials. JAMA, 318(10), 927–938.

Parker, W. H., Feskanich, D., Broder, M. S., Chang, E., Shoupe, D., Farquhar, C. M., Berek, J. S., & Manson, J. E. (2013). Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstetrics and Gynecology, 121(4), 709–716.

Yeap, B. B., Flicker, L., Xiao, J., Norman, P. E., Hankey, G. J., Almeida, O. P., & Almeida, O. (2021). Associations of sex hormones with incident dementia and cognitive decline in older men: The Health in Men Study. The Journal of Clinical Endocrinology & Metabolism, 106(4), 1042-1054.